do you feel this is the same trade off of UI builders like android studio (or msvb6). you do in minutes what you previously did in 2, 3 hours.

is it all the work? no, but it's a part that's early on and have high perceived impact.

then, as you progress, that tool actually gets in the way and a new feature that would take 2 hours, now is around 2 days.

OP here: the title of the thread still links to Derek Lowe's blog post, but the article discussed in the blog post was added to the body of the original post (not by me).

Derek Lowe as a science communicator, and others like him, is sorely needed to understand the real meaning and significance of the study and others. I say that as someone with a PhD in chemistry who's been to plenty of presentations on drug discovery topics.

It's difficult to calibrate statements made by other scientists unless you're well embedded within a field: Is this someone whose opinions matter? Are they the subject matter expert they make themselves out to be? Is this research itself truly impactful? Is it really 5 years until it will be realized outside of academic labs? Etc...

It's difficult to decipher questions around credibility because they rely on real-world interactions and associations that extend beyond the physical tokens of paper counts, publication venues, citations, and author lists that typically lag behind the front of human knowledge which is generated from real-world interactions. It can be simple things, like the insightful question a grad student, with minimal publication history, asks in a seminar.

Of course, the paywall is also unhelpful too, but a good, brief commentary by an appropriate commentator is a better link for 99% of prospective readers compared to most "peer reviewed" (scare quotes because that's a real question nowadays) articles.

Indeed. My plans for a youthful Mohawk are being stymied by the lack of AI promised medical breakthroughs.

Wheres my follicles dammit?

there is a AI designed drug for hair loss that i know of.

its slow-release oral minoxidil formulation called MINX. AI helped with the formulation [1].

its in in similar category as VDPHL01. Hundreds of millions if not a billion dollars has been invested into Veradermics, and their main product is VDPHL01 (also an extended-release oral formulation).

[1] https://x.com/anagenxyz/status/2071601868841595082

A good set of clippers.

Already exists (finasteride), only problem is that it castrates you chemicallym

Absci has a good asset coming out pretty soon that you could try to get on the trial.

>We're all about to come face to face with this reality. This dance can only last so long.

Only for values of 'all' that exclude well-connected members of the billionaire class and their select associates.

if you think the state of the art in this area is something you'll hear about from a guy that looks like santa in an academic journal, your investments deserve what's about to happen to them.

Easily? Have you ever actually learned a second language or an instrument as a child?

There is one!

Ketamin should have huge impacts on neuro/brain plasticity when used properly (i.e. in therapy)

Psilocybin has this effect. Source: I can't remember where I read it, so low confidence.

No thanks. Social media needs less hero worship. Just RSS whoever you like.

Drug discovery scientists think about what they're doing and why ALL THE TIME. AI stuff is just another tool.

It's also worth mentioning that drug development timelines typically exceed the interval in which these technologies have been available (or at least effective). Measuring impact will take a long time.